Maravai Lifesciences Holdings stock kpis
Want to see MRVI full AI Analyst Report?
Adjusted EBITDA by Segment
Maravai Lifesciences Holdings reported adjusted EBITDA by segment of $14.92M in Q3 2026, down 18.9% from Q2 2026 and up 468.2% year over year. The highest value was $200.39M in Q2 2022.
Shows profitability across different business units, highlighting which segments are driving earnings and where there might be opportunities or challenges in cost management.
Nucleic Acid Production has been the swing factor—driving big EBITDA peaks early, collapsing during the post‑COVID/convert-to‑GMP reset, and only recently returning to positive contribution as TriLink shifts to higher‑margin GMP and discovery mix. Biologics Safety Testing (Cygnus) is the steady, high‑margin backbone delivering consistent EBITDA. Management’s guidance and margin commentary signal genuine profit momentum, but sustaining it hinges on converting lumpy GMP/CDMO orders and new GMP product commercialization timing despite a stronger balance sheet.
MRVI Adjusted EBITDA by Segment
| Period | Nucleic Acid Production | Biologics Safety Testing | Total |
|---|---|---|---|
| Q3 2026Sep 30, 2026 | $2.46M | $12.46M | $14.92M |
| Q2 2026Jun 30, 2026 | $7.03M | $11.38M | $18.40M |
| Q1 2026Mar 31, 2026 | $17.26M | $13.56M | $30.82M |
| Q4 2025Dec 31, 2025 | $936.00K | $10.17M | $11.10M |
| Q3 2025Sep 30, 2025 | -$7.92M | $10.54M | $2.63M |
| Q2 2025Jun 30, 2025 | -$7.27M | $10.86M | $3.59M |
| Q1 2025Mar 31, 2025 | -$8.90M | $12.67M | $3.77M |
| Q4 2024Dec 31, 2024 | $3.97M | $9.54M | $13.51M |
| Q3 2024Sep 30, 2024 | $15.46M | $10.93M | $26.38M |
| Q2 2024Jun 30, 2024 | $21.30M | $9.45M | $30.75M |
| Q1 2024Mar 31, 2024 | $10.09M | $13.93M | $24.01M |
| Q4 2023Dec 31, 2023 | $24.00M | $11.60M | $35.60M |
| Q3 2023Sep 30, 2023 | $16.59M | $11.25M | $27.84M |
| Q2 2023Jun 30, 2023 | $14.19M | $10.31M | $24.51M |
| Q1 2023Mar 31, 2023 | $27.87M | $13.75M | $41.62M |
| Q4 2022Dec 31, 2022 | $135.43M | $11.21M | $146.64M |
| Q3 2022Sep 30, 2022 | $133.82M | $13.00M | $146.81M |
| Q2 2022Jun 30, 2022 | $186.29M | $14.10M | $200.39M |
| Q1 2022Mar 31, 2022 | $182.80M | $16.53M | $199.33M |
| Q4 2021Dec 31, 2021 | $163.56M | $12.26M | $175.81M |
| Q3 2021Sep 30, 2021 | $150.35M | $13.60M | $163.95M |
| Q2 2021Jun 30, 2021 | $156.32M | $14.29M | $170.61M |
| Q1 2021Mar 31, 2021 | $95.03M | $14.29M | $109.32M |
| Q4 2020Dec 31, 2020 | $57.69M | $10.95M | $68.64M |
| Q3 2020Sep 30, 2020 | $46.70M | $12.00M | $58.70M |
| Q2 2020Jun 30, 2020 | $10.60M | $9.63M | $20.23M |
| Q1 2020Mar 31, 2020 | $18.83M | $11.94M | $30.77M |

